<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00286208</url>
  </required_header>
  <id_info>
    <org_study_id>1.1.5</org_study_id>
    <nct_id>NCT00286208</nct_id>
  </id_info>
  <brief_title>Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation</brief_title>
  <official_title>A Randomized Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <brief_summary>
    <textblock>
      This open-label, randomized study is being conducted to determine whether a dose of 400 mcg
      of sublingual misoprostol (i.e., under the tongue) taken 24 hours following administration of
      mifepristone 200 mg is effective and acceptable at inducing an abortion compared with
      misoprostol taken orally.

      The goal of this study is to provide answers to the following four questions:

        1. Is a regimen of medical abortion with mifepristone using sublingual misoprostol at least
           as effective as using oral misoprostol up to 63 days since the last menstrual period
           (LMP)?

        2. Are the side effects with sublingual use tolerable for women?

        3. Is sublingual administration of misoprostol acceptable to women?

        4. Is one of the regimens (sublingual or oral) superior in terms of efficacy, safety
           (side-effects) or acceptability?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for surgical completion for incomplete abortions or ongoing viable pregnancies at follow up visit Study day 15.</measure>
    <time_frame>2 weeks after mifepristone administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability for women</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1443</enrollment>
  <condition>Induced Abortion</condition>
  <arm_group>
    <arm_group_label>Sublingual Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400 mcg of sublingual misoprostol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Misoprostol administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone, misoprostol</intervention_name>
    <arm_group_label>Sublingual Misoprostol</arm_group_label>
    <arm_group_label>Oral Misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women presenting for medical abortion who consent to participate

          -  Possibility of final gestational age of less than or equal to 63 days

          -  General good health

          -  Willing to provide contact information for purposes of follow-up

        Exclusion Criteria:

          -  Conditions which contraindicate the use of mifepristone or misoprostol

          -  Women presenting for medical abortion who do not consent to participate
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila Raghavan, M.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rasha Dabash, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Selma Hajri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproductive Health Consultant</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayse Akin, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baskent University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilana Dzuba, MHS</last_name>
    <role>Study Director</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State University of Medicine and Pharmacy</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Planification Familiale de l'Ariana</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Planification Familiale la Bardo</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maternité de La Rabta</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private clinic</name>
      <address>
        <city>Tunis</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Zekai Tahir Burak Women's Health Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MoH Ankara Etlik Maternity and Gyneacological Training Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haydarpaşa Numune Training and Research Hospital Family Planning Clinic</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Maternity and Gyneacological Training and Research Hospital</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Moldova, Republic of</country>
    <country>Tunisia</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2006</study_first_submitted>
  <study_first_submitted_qc>February 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2006</study_first_posted>
  <last_update_submitted>February 18, 2014</last_update_submitted>
  <last_update_submitted_qc>February 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medical abortion</keyword>
  <keyword>mifepristone</keyword>
  <keyword>misoprostol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

